Tarsus expects $715M-$730M 2026 XDEMVY sales while deferring Europe and Japan filings

Earnings Call Insights: Tarsus Pharmaceuticals (TARS) Q3 2026

Management View

• CEO Bobak Azamian framed the quarter around scale and pipeline breadth, saying: "More than 1 million bottles of XDEMVY dispensed, more than $1 billion in cumulative net product sales and a pipeline with the

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.